Symbols

OABI

OmniAb·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

Significant Revenue Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About OABI

Omniab, Inc.

A biotech company that develops and commercializes novel antibody therapeutics

Industry

Biological Technology

Established Date

12/14/2015

Listing Date

09/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.omniab.com

Security Type

Common stock

Office address

5980 Horton Street, Suite 600, Emeryville, CA 94608

Business

Introduction

OmniAb, Inc., was incorporated on December 14, 2015 under the laws of the State of Delaware. The company licenses its proprietary discovery research technology to pharmaceutical and biotechnology partners to support the development of next-generation antibody-based therapies. Its platform utilizes engineered transgenic animals and computer simulation tools to generate and screen a diverse antibody library for drug development.

Company Financials

EPS

OABI has released its 2025 Q4 earnings. EPS was reported at -0.11, versus the expected -0.13, beating expectations. The chart below visualizes how OABI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

OABI has released its 2025 Q4 earnings report, with revenue of 8.38M, reflecting a YoY change of -22.47%, and net profit of -14.18M, showing a YoY change of -8.50%. The Sankey diagram below clearly presents OABI's revenue sources and cost distribution.